All In MedTech

FDA Clearance Tracker · P940013-S010

CIBA VISION (VASURFILCON A) SOFT CONTACT LENSES

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 13, 2010 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 13, 2010

Approved

Time to decision

48 days

Received Feb 24, 2010. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P940013-S010
Device name
CIBA VISION (VASURFILCON A) SOFT CONTACT LENSES
Applicant location
Fort Worth, TX
Received
Feb 24, 2010
Decided
Apr 13, 2010
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P940013

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A MANUFACTURING SITE LOCATED AT P.T. CIBA VISION BATAM, BATAM ISLAND, INDONESIA FOR FRONT-END PROCESSING OF THE DEVICE.

Source documents

Other decisions for Alcon Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.